New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking dat...
Rob Truckenmiller, Senior Vice President, Head of US Vaccines, GSK, emphasized the importance of collaborative efforts and fi...
The Change Healthcare Ransomware Payment Change Healthcare, a key player in the medical services sector owned by UnitedHealth Group, fell victim t...
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announ...
GMP material to be used in Phase Ib study in platinum-resistant ovarian cancer (PROC) patients scheduled to start this year. Previously reported Phase I sa...
Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic supply agreemen...
NeuroKey-3™ measures key biomarkers implicated in neurodegeneration, covering multiple aspects of Alzheimer's Disease and Dementia pathology, ...
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, announced that...
- Biktarvy Now First and Only INSTI-Based Single-Tablet Regimen That is FDA Approved and DHHS Guideline Recommended for People Who are Virologically ...
Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, an...
In a significant breakthrough for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), Boehringer Ingelheim's latest Phase II clinical...
Sanofi-Aventis Groupe announced promising results from its Phase 2 RILECSU study, showcasing rilzabrutinib's ability to significantly reduce itch severity ...
"This new partnership builds on our innovation strategy and will allow us to explore the innovative approach of IL-21 blockage as a possible new pa...
ChatGPT CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 16, 2024 07:00 AM Eastern Standard Time Sarepta Therapeutics, Inc. (NASDAQ:...
© 2025 Biopharma Boardroom. All Rights Reserved.
